ReviewAnesthesiology and pain medicine2017
Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article.
Review in Anesthesiology and pain medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Systematic Review on Herbal Preparations for Controlling Visceral Hypersensitivity in Functional Gastrointestinal Disorders.Current pharmaceutical biotechnology · 2024Pooled it
- Efficacy and Safety of the Adjuvant Use of Probiotic Bacillus clausii Strains in Pediatric Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study.Paediatric drugs · 2023Trial
- Duloxetine as a gut-brain axis modulator in irritable bowel syndrome: neuroimmune, microbiota, and pharmacogenomic perspectives.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Suppression of visceral nociception by C-fiber transmission block using temporal interference sinusoidal stimulation.Pain reports · 2026Article
- Pain management in a patient with intestinal failure in the palliative care setting: case report.BMC palliative care · 2025Article
- Endocannabinoid system modulation for visceral abdominal pain in inflammatory bowel disease and irritable bowel syndrome: A protocol for systematic review and meta-analysis.HRB open research · 2025Article
- Comparisons of different electrical stimulation modalities for treating visceral pain in a rodent model of irritable bowel syndrome.Bioelectronic medicine · 2024Article
- Complex visceral hyperalgesia in an adolescent with Pitt-Hopkins syndrome.BMJ case reports · 2024Article
- Evaluation of the mechanism of action of paracetamol, drotaverine, and peppermint oil and their effects in combination with hyoscine butylbromide on colonic motility: humanFrontiers in pharmacology · 2024Article
- Blocking Aδ- and C-fiber neural transmission by sub-kilohertz peripheral nerve stimulation.Frontiers in neuroscience · 2024Article
- Article
- Effects of Duloxetine on Gastrointestinal Symptoms, Depression, Anxiety, Stress, and Quality of Life in Patients with the Moderate-to-Severe Irritable Bowel Syndrome.Advanced biomedical research · 2023Article
- Editorial: Emerging trends in abdominal and pelvic pain.Frontiers in pain research (Lausanne, Switzerland) · 2023Article
- Long-lasting visceral hypersensitivity in a model of DSS-induced colitis in rats.Neurogastroenterology and motility · 2022Article
- Antispasmodic Effect of Bergamot Essential Oil on Rat Isolated Gut Tissues.Pharmaceutics · 2022Article
- The Associations of Single Nucleotide Polymorphisms with Risk and Symptoms of Irritable Bowel Syndrome.Journal of personalized medicine · 2022Article
- Depression and Pain: Use of Antidepressants.Current neuropharmacology · 2022Review
- Toward Elucidating the Physiological Impacts of Residual Stresses in the Colorectum.Journal of biomechanical engineering · 2022Article
- NUCB2/Nesfatin-1 Regulation of Chronic Visceral Hyperalgesia.Applied bionics and biomechanics · 2022Article
- Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review.Neurology international · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
contextVisceral pain is a leading symptom for patients with irritable bowel syndrome (IBS) that affects 10% - 20 % of the world population. Conventional pharmacological treatments to manage IBS-related visceral pain is unsatisfactory. Recently, medications have emerged to treat IBS patients by targeting the gastrointestinal (GI) tract and peripheral nerves to alleviate visceral pain while avoiding adverse effects on the central nervous system (CNS). Several investigational drugs for IBS also target the periphery with minimal CNS effects. EVIDENCE OF ACQUISITION: In this paper, reputable internet databases from 1960 - 2016 were searched including Pubmed and ClinicalTrials.org, and 97 original articles analyzed. Search was performed based on the following keywords and combinations: irritable bowel syndrome, clinical trial, pain, visceral pain, narcotics, opioid, chloride channel, neuropathy, primary afferent, intestine, microbiota, gut barrier, inflammation, diarrhea, constipation, serotonin, visceral hypersensitivity, nociceptor, sensitization, hyperalgesia.
resultsCertain conventional pain managing drugs do not effectively improve IBS symptoms, including NSAIDs, acetaminophen, aspirin, and various narcotics. Anxiolytic and antidepressant drugs (Benzodiazepines, TCAs, SSRI and SNRI) can attenuate pain in IBS patients with relevant comorbidities. Clonidine, gabapentin and pregabalin can moderately improve IBS symptoms. Lubiprostone relieves constipation predominant IBS (IBS-C) while loperamide improves diarrhea predominant IBS (IBS-D). Alosetron, granisetron and ondansetron can generally treat pain in IBS-D patients, of which alosetron needs to be used with caution due to cardiovascular toxicity. The optimal drugs for managing pain in IBS-D and IBS-C appear to be eluxadoline and linaclotide, respectively, both of which target peripheral GI tract.
conclusionsConventional pain managing drugs are in general not suitable for treating IBS pain. Medications that target the GI tract and peripheral nerves have better therapeutic profiles by limiting adverse CNS effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.